Oncology /Immuno-oncology Platform
Non-Human Primates Platform
Inflammation/Autoimmune Diseases Model
Metabolic/Liver/Cardiovascular Diseases Model
Antibody Screening Platform
Objective: to establish the model about concanavalin A-induced（Con A）experimental liver injury in mice.
Methods: Forty Balb/C mice were randomly divided into 4 groups (ten for each group), A, B, C and D. Con A 10mg/kg, 20mg/kg or 30mg/kg was intravenously (tail vein) injected into the mice in groups A, B and C respectively while normal saline was used for the group D (control group). Activity of alanine transaminase (ALT), death rate and liver histopathological changes were observed after 8 hours of injection. The optimal Con A dose (20mg/kg) was selected, activity of ALT, death rate and liver histopathological changes were observed based on such dosage. Results after 8 hours of injection of Con A, no dead mouse was found in groups A and D, but 3 and 10 mice were dead in groups B and C respectively. Liver histopathology showed only degeneration of liver cells was present in group A, while degeneration, necrosis and liver inflammatory cell infiltration occurred in groups B and C. Within 24 hours of injection of 20mg/kg of Con A, the death rate, activity of ALT, liver inflammatory cells infiltration, hepatocyte degeneration and necrosis exacerbated with the prolongation of time.
Conclusion: the optimal dosage to establish Con A-induced experimental liver injury in mice is 20mg/kg, with the optimal observation time at 8 hours after intravenous (tail vein) injected.